Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Far Infrared Radiation Treatment for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00573820
Recruitment Status : Unknown
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was:  Active, not recruiting
First Posted : December 14, 2007
Last Update Posted : August 17, 2009
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.

Tracking Information
First Submitted Date  ICMJE December 12, 2007
First Posted Date  ICMJE December 14, 2007
Last Update Posted Date August 17, 2009
Study Start Date  ICMJE January 2006
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 12, 2007)
The primary end point is to determine the therapeutic effects of far infrared radiation on Prostate Cancer. [ Time Frame: 2 years and 6 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT00573820 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: December 12, 2007)
The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of cancer (Bladder and Testis). [ Time Frame: 2 years and 6 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Far Infrared Radiation Treatment for Prostate Cancer
Official Title  ICMJE Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer
Brief Summary A study to determine the use of far infrared radiation for the treatment of prostate cancer.
Detailed Description Our initial assessment indicates that electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to cure a number of diseases, including prostate cancer.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostatic Neoplasms
Intervention  ICMJE Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
Study Arms  ICMJE 1
Intervention: Radiation: Far Infrared Radiation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Actual Enrollment  ICMJE
 (submitted: August 14, 2009)
4
Original Estimated Enrollment  ICMJE
 (submitted: December 12, 2007)
2
Estimated Study Completion Date  ICMJE December 2008
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Persons with Prostate, Bladder or Testicular Cancer.

Exclusion Criteria:

  • None
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00573820
Other Study ID Numbers  ICMJE GAAD-PC-CTP1
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc.
Study Sponsor  ICMJE GAAD Medical Research Institute Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Director: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
PRS Account GAAD Medical Research Institute Inc.
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP